Early evidence suggests that newer diabetes drugs might improve liver enzymes and hepatic steatosis and could perhaps be of use in treating non-alcoholic fatty liver disease (NAFLD), researchers say.

Pakistani researchers searched the literature to May 2020 for randomised clinical trials assessing the efficacy of glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, pioglitazone and dipeptidyl-peptidase-4 (DPP-4) inhibitors in treating NAFLD.